The objective of this study was to clarify the mechanism underlying hepatic uptake of dioscin (diosgenyl 2,4-di-O-a-Lrhamnopyranosyl-p-D-glucopyranoside), an herbal ingredient with antihepatitis activity, in rats and humans. The liver uptake index (LUI) in vivo, perfused rat liver in situ, rat liver slices, isolated rat hepatocytes, and human organic anion-transporting polypeptide (OATP)-transfected cells in vitro were used to evaluate hepatic uptake of dioscin. Values of 11.9% 6 1.6% and 15.0% 6 0.9% of dose for uptake of dioscin were observed by LUI in vivo and perfused rat livers in situ, respectively. The time course of dioscin uptake by rat liver slices was temperature-dependent. Uptake of dioscin by rat liver slices and isolated rat hepatocytes was inhibited significantly by Oatp modulators, such as ibuprofen (Oatp1a1 inhibitor), digoxin (Oatp1a4 substrate), and glycyrrhizic acid (Oatp1b2 inhibitor), but not by TEA or p-aminohippurate. Uptake of dioscin in rat hepatocytes and OATP1B3-human embryonic kidney (HEK) 293 cells indicated a saturable process with a K m of 3.75 6 0.51 mM and 2.08 6 0.27 mM, respectively. (-)-Epigallocatechin gallate, cyclosporin A, rifampicin, and telmisartan inhibited transport of dioscin in OATP1B3-HEK293 cells. However, transcellular transport of dioscin in OATP1B1-or OATP1B1/multidrug resistance-associated protein 2-Madin-Darby canine kidney strain II cells was not observed. These results indicate that hepatic uptake of dioscin is involved in OATP1B3 in humans, and multiple Oatps might participate in this process in rats.
Introduction
Saponins, a family of glycoconjugates, have a broad range of pharmacological activity, including antivirus, immunomodulation, and anticancer effects (Sun et al., 2011) . Steroidal saponins are common in traditional medicine plants, such as Dioscorea nipponica Makino. For instance, di-ao-xin-xue-kang capsules prepared from D. nipponica Makino have been used for more than 10 years in China to treat coronary heart disease (Liu et al., 2004b) . The bioactivity of dioscin (diosgenyl 2,4-di-O-a-L-rhamnopyranosyl-p-D-glucopyranoside), a major component of di-ao-xin-xue-kang capsules, has been reported and includes antihepatitis (induced by carbon tetrachloride) (Lu et al., 2011) , antitumor (Mi et al., 2002; Liu et al., 2004a; Hu et al., 2012) , and antifungal (Sautour et al., 2004) activity. Dioscin ( Fig. 1) , a typical example of a spirostane saponin, is a natural saponin that has been isolated from a number of oriental vegetables and traditional medicinal plants. Other groups (Li et al., 2005) have demonstrated that, after an oral dose or intravenous administration at 24 hours in rats, dioscin is distributed primarily in the liver at a concentration 10-or 7-fold higher than that in plasma. However, the mechanism underlying hepatic uptake of dioscin is unclear, and we focused on the hepatic uptake process to examine the pharmacokinetics of dioscin.
Several transporters, such as Na + -taurocholate cotransporting polypeptide and organic anion-transporting polypeptide (OATP) 1B1 [known also as OATP-C, OATP2, LST-1 (liver specific organic anion transporter 1), and SLC (solute carrier) 21A6], OATP1B3 (known also as OATP8, LST-2, and SLC21A8), OATP2B1 (known also as OATP-B and SLC21A9), organic cation transporter 1 (OCT1, SLC22A1), and organic anion transporter 2 (OAT2, SLC22A7), are expressed on the sinusoidal membrane of hepatocytes. These proteins are involved in transport of a wide variety of compounds, including clinical drugs (such as statins) from blood into hepatocytes (Hsiang et al., 1999; König et al., 2000; Tamai et al., 2000; Faber et al., 2003; Hirano et al., 2004; Shitara et al., 2006; De Bruyn et al., 2011) . In particular, OATP1B1 and OATP1B3, expressed mainly on the sinusoidal membrane of human hepatocytes (Faber et al., 2003) , are thought to exert a significant influence on the removal of various endogenous and xenobiotic substances from the bloodstream into hepatocytes (Smith et al., 2005; Hagenbuch and Gui, 2008; Kindla et al., 2009 ). The substrate specificity of OATP1B1 generally overlaps that of OATP1B3. However, there are some discrepancies between them, e.g., telmisartan (an angiotensin II antagonist) is a substrate of OATP1B3 but not OATP1B1 (Ishiguro et al., 2006; Giacomini et al., 2010) .
In this study, we used the liver uptake index (LUI) method in vivo, perfused rat liver in situ, rat liver slices, and isolated rat hepatocytes in vitro as well as human OATP1B3-and OATP1B1-transfected cells to investigate the involvement of OATPs in hepatic uptake of dioscin.
Materials and Methods
Chemicals. Dioscin (with a purity of .99%) was provided by Professor Jinyong Peng (College of Pharmacy, Dalian Medical University, Dalian, China). Telmisartan was provided by Zhejiang Kinglyuan Pharmaceutical Co., Ltd. (Shangyu, China). TEA, digoxin, and glycyrrhizic acid were purchased from Hubei Saibo Chemical Co., Ltd. (Wuhan, China) and Nanjing ZeLang Medical Technology Co., Ltd. (Nanjing, China), respectively. Cyclosporin A, rifampicin, and (-)-epigallocatechin gallate were purchased from the National Institute for the Control of Pharmaceutical and Biologic Products (Beijing, China). p-Aminohippurate (PAH), hydrochlorothiazide [internal standard (IS)], inulin, (RS)-2-(4-(2-methylpropyl)phenyl)propanoic acid (ibuprofen), and estrone-3-sulfate (E3S) were purchased from Sigma-Aldrich (St. Louis, MO). All other chemicals were of analytical grade and were commercially available.
Cell Culture. The stable transfected OATP1B3-human embryonic kidney (HEK) 293 cells, vector-HEK293 cells, and vector-, OATP1B1-, and OATP1B1/ MRP (multidrug resistance-associated protein) 2-Madin-Darby canine kidney strain II (MDCKII) cells were a gift from Yuichi Sugiyama (Graduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo, Japan). HEK293 cells and MDCKII cells were grown in low-glucose Dulbecco's modified Eagle's medium (Invitrogen, Carlsbad, CA) supplemented with 10% (v/v) fetal bovine serum (Invitrogen), 100 U/ml of penicillin, and 100 mg/ml of streptomycin at 37°C with a 5% (v/v) CO 2 atmosphere and 95% relative humidity. Cell culture reagents were purchased from Gibco (Grand Island, NY).
Animals. Male Wistar rats with body weights of 220-250 g, obtained from the Experimental Animal Center of Dalian Medical University (permit number SCXK 2008-0002), were allowed free access to water and chow diet but were fasted for 12 hours (with water ad libitum) before the experiments. All of the animal experiments were conducted according to local institutional guidelines for the care and use of laboratory animals.
In Vivo LUI Studies. Under light ether anesthesia, the portal vein was cannulated with polyethylene tubing (PE-50; BD Biosciences, Franklin Lakes, NJ) in male Wistar rats. A 2-ml/kg bolus of normal saline, cyclosporin A (9.6 mg/kg), or rifampicin (20 mg/kg) was given by jugular vein 5 minutes before the administration of dioscin and inulin. Dioscin (0.2 mg/kg body weight) and inulin (1 mg/kg body weight) dissolved in rat plasma, which was used for the bolus intravenous administration, was injected rapidly into the portal vein immediately after ligation of the hepatic artery. After 18 seconds of bolus administration of compounds, which is enough time for the bolus to pass completely through the liver but brief enough to prevent recirculation of the compounds (Liu et al., 1992) , the portal vein was cut, and the liver was excised, weighed, and stored at -20°C.
In Situ Perfused Rat Liver Experiments. Livers of male Wistar rats were prepared by standard techniques (Meng et al., 2010) . Following anesthesia, the bile duct was cannulated, and the liver was perfused in situ in a single pass via the portal vein with oxygenated Krebs-Henseleit buffer (Meng et al., 2010) . The liver was allowed to equilibrate for approximately 10 minutes before addition of the dose. Perfusion was continued with oxygenated Krebs-Henseleit buffer containing 20% (v/v) washed bovine erythrocytes at a flow rate of 12 ml/min. The superior vena cava was cannulated and used to collect the effluent perfusate. Liver viability was determined on the basis of the initial bile flow (.2 ml/min). Following equilibration, the liver was perfused for 60 minutes after addition of dioscin 2.5 mM, dioscin 2.5 mM + cyclosporin A 10 mM, or dioscin 2.5 mM + rifampicin 10 mM (final concentration). The effluent perfusate (;500 ml) was collected at timed intervals, and the samples were stored at -20°C.
In Vitro Uptake in Rat Liver Slices. Rat liver slices were prepared as previously described (Elferink et al., 2004) . In brief, after the anesthetic, the liver of male Wistar rats was excised and immediately placed into ice-cold buffer, saturated with carbogen (95% O 2 /5% CO 2 ; pH 7.4), and then cut into slices with a ZQP-86 tissue slicer (200-300-mm thickness; Zhixin Co., Ltd., Shanghai, China). After preincubation for 3 minutes at 37°C, the liver slices were transferred to 24-well culture plates containing fresh carbogen-saturated dioscin for further incubation. In addition, uptake of dioscin (5 mM) and digoxin (5 mM) was measured at 0, 1, 5, 15, and 30 minutes, and the liver slices were rinsed with ice-cold Hanks' balanced salt solution (pH 7.5) and dried on filter paper. According to the result of time-dependent experiment, 15 minutes was chosen as an uptake time that represented the overall rate of uptake, and was used to examine the effects of inhibitors (detailed specificities of inhibitors against rat Oatps can be found in Supplemental Table 1 ), including PAH (1 mM), TEA (1 mM), cyclosporin A (10 mM), ibuprofen (100 mM), digoxin (5 mM), rifampicin (10 mM), and glycyrrhizic acid (100 mM), on the uptake of dioscin. The accumulated dioscin and digoxin in homogenized liver slices were determined by liquid chromatography-tandem mass spectrometry (LC-MS/MS).
Uptake Using Isolated Rat Hepatocytes. Isolated rat hepatocytes were prepared by the collagenase perfusion method in male Wistar rats as previously described (Maeda and Sugiyama, 2010) . Isolated hepatocytes (viability .80%, determined by staining with Trypan blue) were suspended in Krebs-Henseleit buffer, adjusted to 2.0 Â 10 6 cells/ml and kept on ice. To examine the sodium dependence of dioscin (2.5 mM) uptake by rat hepatocytes, experiments were done in Krebs-Henseleit buffer but with sodium replaced by potassium. Before the uptake study, the cell suspension and Krebs-Henseleit buffer containing the substrate were incubated separately at 37°C for 3 minutes, and then transport was initiated by adding an equal volume of buffer (120-200 ml) to the cell suspension. After incubation at 37°C for 0.5, 1, 2, or 5 minutes, the reaction dmd.aspetjournals.org was terminated by separating the cells from the substrate solution by centrifugal filtration. For this purpose, a 100-ml sample of incubation mixture was collected and placed into a 450-ml centrifuge tube (Hepatocyte Transporter Suspension Assay Kit; BD Gentest, Woburn, MA) containing 5 M sodium acetate under a 100-ml layer of an oil mixture (density 1.015, a mixture of silicone oil and mineral oil; BD Gentest), which was centrifuged at 10,000g for 10 seconds (ST-16R, Thermo Fisher Scientific, Waltham, MA), and the hepatocytes passed through the oil layer into the aqueous solution. The tube contents were frozen in liquid nitrogen immediately after centrifugation and stored at 220°C.
Uptake Experiments Using Transporter Expression Systems. The transport study was done as described previously (Hirano et al., 2004) . Briefly, the assays were conducted in 24-well culture plates with nearly confluent cells seeded 48 hours before each experiment. Uptake was initiated by adding KrebsHenseleit buffer (Hirano et al., 2004) containing dioscin after the cells had been washed twice and incubated with Krebs-Henseleit buffer at 37°C for 15 minutes. The uptake was terminated at designated times by adding ice-cold KrebsHenseleit buffer after removal of the incubation buffer. The cells were washed twice with 1 ml of ice-cold Krebs-Henseleit buffer, lysed with 0.3 ml of 0.1% (v/v) Triton X-100, then transferred to a polyethylene tube for quantization by LC-MS/MS. Protein was measured by the bicinchoninic acid procedure (Solarbio, Beijing, China) using bovine serum albumin as the standard.
The uptake of dioscin (2.5 mM) was measured at designated times in OATP1B3-and vector-HEK cells. According to the results, a time of 1 minute was selected as representative of the uptake rate and was used to examine the concentration-dependent uptake and the effects of transporter modulators on the uptake of dioscin.
Transcellular Transport. The transcellular transport study was performed essentially as described previously (Matsushima et al., 2005) , but with modifications. In brief, 24-well Transwell inserts (12 mm diameter, 0.6 cm 2 growing surface area, 0.4 mm pore size; Corning Costar, Acton, MA) were used to seed the vector-, OATP1B1-, and OATP1B1/MRP2-transfected MDCKII cells with a density of 1.4 Â 10 5 cells per well. After incubation for 3-5 days of MDCKII cells until confluence, the integrity of the cell monolayer was evaluated by measuring the transepithelial electrical resistance (.200 V·cm 2 ) using Millicell Electrical Resistance System equipment (Millipore, Billerica MA). The monolayer cells were rinsed gently with transport buffer (Matsushima et al., 2005) at 37°C, and the transwell chambers were incubated for 15 minutes. Subsequently, transepithelial transport experiments were initiated by adding incubation buffer containing dioscin (2.5 mM, final concentration) or E3S (1 mM) to the apical (400 ml) or basolateral (600 ml) compartment. Cells were incubated at 37°C under a 5% (v/v) CO 2 atmosphere, and 50 ml aliquots in the receiver compartment were sampled at 30, 60, 120, and 180 minutes. An equal volume of transport buffer was added to the sampling compartment immediately after sample retrieval. Intracellular accumulation was measured by aspirating the medium and washing the monolayer rapidly four times with transport buffer on each side. The inserts with a monolayer were detached from the chambers, and cells were lysed by addition of 0.3 ml of 0.1% (v/v) Triton X-100. The concentration of dioscin and E3S in the uptake and transepithelial transport samples was determined by LC-MS/MS.
Determination of the Plasma Protein-Unbound Fraction and Blood/ Plasma Concentration Ratio. Binding of dioscin to plasma proteins was determined by an ultrafiltration method (Watanabe et al., 2009 ). To estimate the fraction not bound to plasma protein (f u ), 2.5 mM dioscin was added to rat plasma samples (obtained from male Wistar rats) and incubated at 37°C for 30 minutes. Then, the samples underwent ultrafiltration (Millipore). The concentrations of dioscin in the plasma and filtrate were determined by LC-MS/ MS, and the plasma protein unbound fraction was calculated. In a pilot study, no significant difference of protein binding was confirmed up to its concentration of 20 mM. The adsorption of the drugs on the membrane was confirmed to be negligible.
To determine the blood/plasma concentration ratio (R B ) values of dioscin, dioscin was added to the blood samples, and they were incubated together at 37°C for 5 minutes. Plasma was prepared by centrifugation of the blood samples at 2795g for 10 minutes at 4°C. The concentrations of dioscin in the blood and the plasma samples were determined by LC-MS/MS.
Biologic Sample Preparation. Each liver obtained from the LUI study was weighed, added to a 3-fold volume of normal saline, and homogenized (IKA-T10 homogenizer; IKA, Staufen, Germany) in an ice bath. For the inulin preparation, inulin was measured as 5 -(hydroxymethyl) furfural after acid and heat treatment (Lin et al., 2010) . Briefly, homogenate samples were precipitated with 7% (v/v) HClO 4 , and then through boiling, cooling, and solid phase extraction processes, the eluate was collected and dried with pure nitrogen gas. Finally, the residue was reconstituted with the mobile phase. For the dioscin preparation, the homogenate (50 ml) obtained from the LUI studies was precipitated with 200 ml of acetonitrile following the addition of 50 ml of IS solution (800 ng/ml). Subsequently, the mixture was vortex mixed and centrifuged, and then the supernatant organic layer was dried with nitrogen at 37°C. The dried residue was dissolved in 200 ml of the mobile phase. The liver slice samples were weighed and then mixed with 300 ml of normal saline and homogenized in an ice bath. The other preparations were handled as described for the LUI-homogenized samples for dioscin. Cells in 5 M sodium acetate buffer from the rat hepatocytes uptake study were taken from the centrifuge tube, placed into a fresh tube, and sonicated. Then 50 ml of the IS solution and Fig. 2 . The hepatic extraction ratio of dioscin in the presence or absence of cyclosporin A/rifampicin in the LUI experiment (A) and perfused rat liver experiment (B). (A) Dioscin or inulin was injected rapidly into the portal vein, the liver was excised, and concentration of dioscin or inulin was measured by LC-MS/MS as described in the text. Each value was normalized by the total injected dose. (B) Rat livers were perfused with 2.5 mM dioscin, and the hepatic extraction ratio was calculated from the concentration of dioscin in the effluent and the influent perfusate. *P , 0.05, a significant difference from the hepatic extraction in dioscin only group. at ASPET Journals on June 13, 2017 dmd.aspetjournals.org Downloaded from 500 ml of water were added. After vortex mixing for 10 seconds, 1 ml of diethyl ether, the extraction solvent, was added and vortex mixed for 3 minutes and then centrifuged for 10 minutes at 2795g. The supernatant organic layer was dried with nitrogen at 37°C, and the dry residue was dissolved in 200 ml of the mobile phase. The uptake and transepithelial transport, blood, and plasma samples were handled as described for LUI-homogenized samples for dioscin. The samples of digoxin and E3S for liver slices and rat hepatocytes, which were used as the positive control, were handled as described for dioscin. The samples were subjected to LC-MS/MS analysis.
LC-MS/MS Analysis. An Agilent LC system (Agilent HP1200; Agilent Technology, Palo Alto, CA) was used for LC-MS/MS analysis. Isocratic chromatographic separation was performed by passage through a Hypersil BDS-C18 column (150 Â 4.6 mm i.d., 5 mm; Dalian Elite Analytical Instruments Co. Ltd., Dalian, China). The mobile phase consisted of 70% (v/v) acetonitrile, 30% (v/v) water with 0.1% (v/v) formic acid for inulin, 80% (v/v) acetonitrile, 10% (v/v) methyl alcohol, and 10% (v/v) water with 10 mmol/l aqueous ammonium acetate for dioscin, 70% (v/v) methyl alcohol, 30% (v/v) water with 0.1% formic acid for digoxin, 70% (v/v) acetonitrile, 10% (v/v) methyl alcohol, and 20% (v/v) water with 10 mmol/l aqueous ammonium acetate for E3S at a flow rate of 0.5 ml/min. The column was maintained at ambient temperature. An API 3200 triple-quadruple mass spectrometer (Applied Biosystems, Concord, ON, Canada) was operated with a TurboIonSpray interface in positive ion mode for inulin and in negative ion mode for dioscin, digoxin, E3S, and IS. Analyst 1.4.1 software (Applied Biosystems) was used to control the equipment, data acquisition, and analysis. Multiple reactions monitoring was used for data acquisition. The optimized truncated multiple reactions monitoring fragmentation transitions were m/z (mass-to-charge ratio) 127.1 → 109.1 with a collision energy (CE) of 20 eV for 5-(hydroxymethyl) furfural (converted from inulin), m/z 867.5 → 721.5 with a CE of -50 eV for dioscin, m/z 779.0 → 649.0 with a CE of -50 eV for digoxin, m/z 348.9 → 268.9 with a CE of -45 eV for E3S, and m/z 295.6 → 204.8 with a CE of -50 eV for IS. The dwell time for each transition was 200 ms.
Data Analysis. Data obtained in the LUI studies were expressed as a percentage of LUI, which represents the ratio of the hepatic extraction of dioscin to that of inulin. The LUI was obtained as (Liu et al., 1992) : where X dioscin and X inulin are the amount of dioscin remaining in the liver after injection. Dioscin and inulin, taken up by the liver or in the injectate, were measured by LC-MS/MS analysis. The hepatic extraction ratio (E h ) and clearance (CL h, in situ ) of dioscin in perfused rat liver were calculated as:
where C out and C in are the concentration of dioscin in the effluent perfusate and the influent perfusate, respectively. F h represents the bioavailability of liver. CL int, h and f (f = 1) represent the intrinsic hepatic clearance and the protein unbound fraction in perfusate, respectively. Hepatic blood flow rate (Q h ) was set at 60 ml/min/kg (Davies and Morris, 1993; Watanabe et al., 2009 ). The in vitro uptake clearance (CL h, in vitro ) in rat isolated hepatocytes was calculated by dividing initial uptake velocity by the concentration of dioscin in the incubation buffer. The initial uptake velocity of dioscin was calculated as a slope of the uptake volume (ml/10 6 cells) at 0.5 and 2 minutes.
In the well-stirred model in vivo (Maeda and Sugiyama, 2010) , hepatic clearance (CL h, predicted ) is expressed as a function of intrinsic hepatic clearance (CL int, h ), hepatic blood flow rate (Q h ), and the protein unbound fraction in blood (f B ):
where f u and R B represent protein unbound fraction in plasma and the blood/ plasma concentration ratio (R B ) of drug. Specific uptake was obtained by subtracting the uptake into vector-transfected cells from the uptake into OATP-transfected cells. Kinetic parameters were obtained using nonlinear, least-squares regression analysis via the MichaelisMenten equation:
where v is the uptake velocity of the substrate (pmol/min per milligram of protein), K m is the Michaelis constant (mmol), S is the substrate concentration in the medium (mmol), and V max is the maximum uptake rate (pmol/min per milligram of protein). The calculation of IC 50 values was performed using Prism 5 (GraphPad Software Inc., La Jolla, CA). Then inhibition constant (K i ) values were obtained as (Liu et al., 2011) :
where K m is the Michaelis constant (mmol) and [S] is the substrate concentration (mmol). Each experimental point represents the mean 6 S.D. of 3-6 measurements. All statistical analyses were conducted with the SPSS11.5 package (IBM SPSS Inc, Chicago, IL). Test results are expressed as the mean 6 S.D., and differences with P # 0.05 are considered to be statically significant.
Results

LUI
Study. An LUI study was performed with rats to evaluate the hepatic extraction of dioscin in vivo. The LUI value was obtained by injecting dioscin directly into the portal vein. By correcting for nonspecific distribution to the interstitial space and retention in the vascular space in the liver ( Fig. 2A) , the LUI value, calculated with eq. 1, was 11.9% 6 1.6%. Cyclosporin A and rifampicin showed significant inhibition in hepatic extraction of dioscin, with decreased LUI values of 6.9% 6 1.2% and 5.5% 6 0.7%, respectively ( Fig. 2A) .
Perfused Rat Liver. After perfusion of dioscin (2.5 mM) into rat liver at a constant rate, the effluent perfusate samples were collected at 1, 5, 10, 15, 20, 30, 45, and 60 minutes; bile samples were collected at 15-minute intervals. The concentration reached a plateau after 30 minutes and remained constant until the end of the perfusion (Fig. 2B) . The value for the hepatic extraction ratio calculated by eqs. 2 and 3 was 15.0% 6 0.9%. Moreover, this value was reduced to 7.4% 6 1.1% and 8.2% 6 1.6% when dioscin was administered simultaneously with cyclosporin A and rifampicin (Fig. 2B) . Based on eqs. 3 and 5, the intrinsic hepatic clearance in situ was obtained, and hepatic clearance of dioscin (CL in situ, predicted ), calculated by the well-stirred model (eqs. 6 and 7), was 0.83 6 0.10 ml/min/kg.
Effects of Transporter Modulators on Dioscin Uptake in Rat Liver Slices. Liver slice uptake experiments were used to elucidate the target transporters involved in dioscin accumulation in the liver. The uptake of dioscin (5 mM) at 37°C was linear within the first 15 minutes. A significant difference was found between the amount of dioscin uptake in the liver slices at 4°C and at 37°C (Fig. 3B) . Under the present experimental conditions, digoxin was used as a positive control (Fig. 3A) . We investigated the inhibitory effects of transporter modulators on dioscin uptake to determine the mechanism for dioscin uptake by the liver. The initial uptake of dioscin in rat liver slices was inhibited significantly in the presence of cyclosporin A (10 mM), ibuprofen (100 mM), digoxin (5 mM), rifampicin (10 mM), and glycyrrhizic acid (100 mM), respectively. By contrast, TEA (1 mM) and PAH (1 mM) did not inhibit the uptake of dioscin (Fig. 3C) .
Characterization of Dioscin Uptake by Isolated Rat Hepatocytes. We used isolated rat hepatocytes to investigate the uptake of dioscin to further examine transporter-mediated dioscin uptake. The uptake of dioscin (2.5 mM) and digoxin (5 mM) by rat hepatocytes increased linearly up to 2 minutes (Fig. 4, A and B) , and the uptake of dioscin at 1 minute was used in subsequent studies. The uptake of dioscin in rat hepatocytes was a saturable process, with K m = 3.75 6 0.51 mM and V max = 588 6 12 pmol/min per 10 6 cells (Fig. 4C ). In addition, we examined the inhibitory effects of transporter modulators. Uptake of dioscin was inhibited significantly by cyclosporin A, ibuprofen, digoxin, rifampicin, and glycyrrhizic acid, but not by TEA or PAH (Fig. 5) . Moreover, when extracellular sodium ions were replaced with potassium ions at an equimolar concentration, the uptake of dioscin was not changed (Fig. 5) .
Comparison of the Hepatic Clearance of Dioscin Obtained from In Situ with That from In Vitro. The hepatic clearance (CL h, in situ ) of dioscin in perfused rat liver in situ calculated by eqs. 2-4 was 9.0 6 0.5 ml/min/kg. Based on the in vitro data in rat hepatocytes, the intrinsic uptake clearance (CL int, h ) was obtained, and the hepatic clearance of dioscin (CL h, predicted ), calculated by the well-stirred model with eqs. 6-8, was 10.8 6 0.7 ml/min/kg (Table 1) . Therefore, the CL h, in situ in situ could be well consistent with the CL h, predicted in vitro.
Uptake of Dioscin by Transporter-Expressing HEK293 Cells. The uptake of dioscin by HEK293 cells expressing OATP1B3 and vector was measured to examine whether dioscin can be transported by human hepatic transporters. The uptake of dioscin (2.5 mM) in OATP1B3-HEK293 cells was significantly higher than that of vector-HEK293 cells (Fig. 6A) . Eadie-Hofstee plot analysis indicated that the K m and V max values of dioscin were 2.08 6 0.17 mM and 730 6 17 pmol/min per milligram of protein, respectively (Fig. 6B) .
Inhibitory Effects of Drugs on Uptake of Dioscin in OATP1B3-HEK293 Cells. The effects of cyclosporin A, rifampicin, (-)-Epigallocatechin gallate, and telmisartan on the cellular uptake of dioscin were Fig. 5 . Effects of sodium ions and transporter modulators on the uptake of dioscin in isolated rat hepatocytes. The substrate concentration was 2.5 mM. The results are shown as a percentage of dioscin uptake measured in the absence of inhibitor and in the presence of sodium ions. *P , 0.05, a significant difference from the uptake in control group. (Fig. 7) . All potential inhibitors were used in a concentration range of 0.1-500 mM, whereas dioscin was used at a concentration of only 1 mM. All clinical drugs inhibited dioscin uptake significantly. K i values for dioscin calculated by eq. 10, which are summarized in Table 2 , show the following order of potency for OATP1B3 inhibition: telmisartan.cyclosporin A.rifampicin.EGCG. Transcellular Transport of Dioscin in OATP1B1-MDCKII Cells. To characterize the activity of double-transfected MDCKII cells coexpressing OATP1B1 and MRP2, we evaluated the transcellular transport of E3S (probe substrate of OATP1B1) across the MDCKII monolayer expressing uptake and efflux transporters (Fig. 8, A-C) . The basal-to-apical transport of E3S was approximately 2.8-and 4.2-fold higher than that in the opposite direction in OATP1B1-and OATP1B1/ MRP2-MDCKII cells, respectively (Fig. 8, B and C) . On the other hand, a symmetrical flux of E3S was observed across the vector-MDCKII cells (Fig. 8A) . This indicates that the activity of OATP1B1 was maintained in this study. The basolateral-to-apical and apical-tobasolateral vectorial transport of dioscin was similar in vector-MDCKII cells (Fig. 8D) . However, no significant difference in vectorial transport was found in OATP1B1-and OATP1B1/MRP2-MDCKII cells between basolateral-to-apical and apical-to-basolateral transport (Fig. 8, E and  F) . Moreover, cellular accumulations of dioscin in vector-, OATP1B1-, and OATP1B1/MRP2-MDCKII cells (Fig. 9) corresponded well with the results of transcellular transport experiments.
Discussion
We investigated the hepatic transport mechanisms of dioscin by an in vivo hepatic extraction study using the LUI method, an in situ uptake study using perfused rat livers, and an in vitro uptake study using rat liver slices, isolated rat hepatocytes, OATP1B3-expressing HEK293, and OATP1B1-and OATP1B1/MRP2-expressing MDCKII cells. The results provide direct evidence that uptake of dioscin by the liver is mediated by transporters of the OATP family, including OATP1B3 in humans (Figs. 6A and 8, D-F) and multiple Oatps (Oatp1a1, Oatp1a4, and Oatp1b2) in rats (Figs. 3C and 5) .
Dioscin, a spirostane saponin with antihepatitis activity (Lu et al., 2011) , accumulates in the liver after intravenous or oral administration at a concentration much higher than dioscin in plasma and other tissues (Li et al., 2005) . The value of hepatic clearance (CL in situ, predicted = 0.83 6 0.10 ml/min/kg) is 21.5% of plasma clearance (3.86 6 0.51 ml/min/kg) (Li et al., 2005) . In addition, Li et al. (2005) reported that dioscin might be metabolized by the liver. These phenomena indicate that the liver may play an un-negligible role in the elimination of dioscin in rats. Therefore, detailed investigation of hepatic uptake is crucial for understanding the pharmacokinetics of dioscin in rats and humans. Initially, the LUI study showed that the LUI of dioscin in vivo was 11.9% 6 1.6% ( Fig. 2A) , which corresponds well with the result (15.0% 6 0.9%) obtained by a liver perfusion study in situ (Fig. 2B) . Further, we also found the significant inhibitory effects of cyclosporin A and rifampicin on liver uptake of dioscin in situ and in vivo (Fig. 2) , indicating that dioscin was extracted by rat liver through hepatic transporters belonging to the Oatp family. After incubation for 30 minutes, uptake of dioscin in rat liver slices was 3.2-fold greater at 37°C than that at 4°C (Fig. 3B) . The uptake of dioscin in the liver at 4°C might be explained by nonspecific membrane binding or intracellular binding after passive diffusion into the cells (Proost et al., 2006) . The difference in drug uptake at 4°C and at 37°C indicates that uptake of dioscin in the liver was mediated by a hepatic transporter. Furthermore, there was marked inhibition of dioscin uptake (Fig. 3C) by cyclosporin A, ibuprofen, digoxin, rifampicin, and glycyrrhizic acid as specific inhibitors of different Oatp isoforms in rats (Supplemental Table 1 ) at concentrations significantly exceeding their respective K i values (Shitara et al., 2002; Ismair et al., 2003) . By contrast, a high concentration of TEA (1 mM) and PAH (1 mM) did not inhibit uptake of dioscin. These results indicate that the transporters of the OATP family might be involved in the uptake of dioscin in rat liver slices.
We characterized the transport property of dioscin using isolated rat hepatocytes. Dioscin transport into rat hepatocytes is time-and concentration-dependent (Fig. 4, B and C) . The apparent K m of dioscin was 3.75 6 0.51 mM in rat hepatocytes. These results indicate that uptake of dioscin in hepatocytes is a transporter-mediated process. To speculate what kind of transporters are responsible for hepatic uptake of dioscin, uptake was examined in the presence of various typical inhibitors of hepatic transporters (Fig. 5) . As expected, a decrease in dioscin uptake was not observed when sodium was replaced by potassium in the incubation medium, suggesting that Na + -independent Oatps are involved mainly in hepatic uptake of dioscin in rats, and Na + -dependent Na + -taurocholate cotransporting polypeptide is not (Nakakariya et al., 2008) . The lack of inhibition of dioscin uptake in rat hepatocytes by PAH and TEA corresponded well with what was found for liver slices, indicating that dioscin is not transported by Oat2 or organic cation transporter (Oct) 1 in the liver (Sugiyama et al., 2001; Ishiguro et al., 2006) . However, cyclosporin A (Oatp1a1 and Oatp1a4 inhibitor), ibuprofen (Oatp1a1 inhibitor), digoxin (Oatp1a4 substrate), rifampicin (Oatp1a4 inhibitor), and glycyrrhizic acid (Oatp1b2, Oatp1a1, and Oatp1a4 inhibitor) inhibited dioscin uptake significantly, which suggests that these individual Oatp-mediated transport processes are important in the uptake of dioscin in isolated rat hepatocytes (Sugiyama et al., 2001; Shitara et al., 2002; Ismair et al., 2003) . The relationship of hepatic clearance for dioscin between isolated rat hepatocytes in vitro and perfused rat liver in situ was also investigated. The predicted CL h, predicted in vitro (Table 1) was comparable with the CL h, in situ observed in the present in situ study, suggesting that these experimental systems were a useful tool for investigating the liver extraction process of drugs. However, CL h, predicted and CL h, in situ are not comparable with CL in situ, predicted in situ. This phenomenon was true in rats for an unknown reason. At the same time, Watanabe et al. (2011) reported that the hepatic clearance of rosuvastatin as well as fluvastatin was an outlier extrapolated from in vitro to in vivo, and that result held true in rats for an unknown reason. Results from both series of experiments point to a possible mechanism of active dioscin uptake by the liver through multiple Oatp isoforms (Oatp1a1, Oatp1a4, and Oatp1b2) as the major underlying transporters for this liver extraction process.
To determine directly the potential of OATPs for the transport of dioscin, we evaluated the transport properties of dioscin using HEK293 cells expressing OATP1B3 and MDCKII cells expressing OATP1B1 and OATP1B1/MRP2 systems. Initially, we investigated the function of transfected cells to confirm that this experimental system is reliable (Fig. 8, A-C) . In transport studies, timeand concentration-dependent uptakes of dioscin were observed in OATP1B3-HEK293 cells (Fig. 6 ). The K m value was 2.08 6 0.17 mM, similar to that for uptake by rat isolated hepatocytes. However, no significant transcellular transport of dioscin was observed in OATP1B1-and OATP1B1/MRP2-expressing cells (Fig. 8, E and F) . These results suggest that dioscin is transported into hepatocytes by OATP1B3 rather than OATP1B1 in humans. Generally, it is accepted that OATP1B1 is responsible for the hepatic uptake of several compounds, such as pitavastatin (Hirano et al., 2004) , which are transported mainly by OATP1B1. Recent studies suggest that fexofenadine and telmisartan are transported by OATP1B3 rather than OATP1B1 (Shimizu et al., 2005; Ishiguro et al., 2006) . Moreover, in valsartan, the contribution of OATP1B1 and OATP1B3 to hepatic uptake is estimated to be similar (Yamashiro et al., 2006) . Therefore, estimating whether a compound or drug is transported by OATP1B1/OATP1B3 in the liver should depend on the properties and chemical structures of the compound or drug.
The effect of drugs on uptake of dioscin in OATP1B3-expressing HEK293 cells was investigated to estimate potential herb-drug interactions with coadministered drugs that are OATP substrates or inhibitors (Fig. 7) . As shown in Table 2 , cyclosporin A is a potent OATP inhibitor; K i for OATP1B3-mediated dioscin uptake was 1.43 mM, which was similar to peak plasma concentrations of cyclosporin A obtained from the literature (Treiber et al., 2007) . This strong inhibitory effect is consistent with the literature for cyclosporin A concerning uptake of bosentan (IC 50 values for OATP1B1 and OATP1B3: 0.3 and 0.8 mM, respectively) (Treiber et al., 2007) . Rifampicin inhibited the dioscin uptake mediated by OATP1B3, with K i = 4.55 mM, whereas plasma concentrations of rifampicin at a therapeutic dose of 600 mg/day are in the range of 8-15 mM (Acocella, 1978; Loos et al., 1985) . Assuming a free fraction of 20%, the free rifampicin serum concentration initially amounts to approximately 1.6-3.0 mM and, thus, lies in a range similar to the apparent rifampicin K i value for OATP1B3-mediated dioscin uptake (Table 2 ). In fact, rifampicin (OATP inhibitor) could affect the hepatic uptake of drugs such as pitavastatin (K i for OATP1B1: 0.5 mM) and bosentan (IC 50 values for OATP1B1 and OATP1B3: 3.2 and 1.6 mM, respectively) (Hirano et al., 2006; Treiber et al., 2007) . Therefore, the hepatic uptake of dioscin might be influenced if dioscin is administered simultaneously with drugs known to be substrates or inhibitors of OATPs.
Herbal medicines are becoming popular worldwide, although their mechanisms of action are generally unknown. More than one-third of adults use herbal medicines in the hope of promoting health and to manage common maladies, such as inflammation, heart disease, and diabetes (Zhou et al., 2007) . Recently, clinically relevant herb-drug interactions based on cytochrome P450 enzymes/drug transporters in the liver have been reported for St. John's wort (Hypericum perforatum) and cyclosporine/digoxin (Ruschitzka et al., 2000; Borrelli and Izzo, 2009 ). Our results indicate that, if dioscin is administered simultaneously with rifampicin or cyclosporin A, the hepatic uptake of dioscin might be influenced ( Fig. 2; Table 2 ). Finally, antihepatitis activity of dioscin might be changed. To date, only a very small proportion of currently available drugs have been investigated for their potential interaction with herbs, such as St. John's wort and ginkgo (Ginkgo biloba) in humans (Zhou et al., 2007) . Thus, further clinical studies are required to gain knowledge of transporter-based herb-drug interactions.
In conclusion, our results demonstrate for the first time that uptake of dioscin by the liver is mediated by a hepatic transport system belonging to the OATP family, including OATP1B3 in humans and multiple Oatps (Oatp1a1, Oatp1a4, and Oatp1b2) in rats. The hepatic uptake of dioscin might be influenced when herbs containing dioscin are administered simultaneously with drugs that are substrates or inhibitors of OATP1B3.
